Cargando…
Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside
The melanocortin-4 receptor (MC4R) is critical for central satiety regulation, therefore presenting a potent target for pharmacological obesity treatment. Melanocortin-4 receptor mutations prevalently cause monogenetic obesity. A possibility of overcoming stop mutations is aminoglycoside-mediated tr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697516/ https://www.ncbi.nlm.nih.gov/pubmed/36362948 http://dx.doi.org/10.3390/life12111793 |
_version_ | 1784838583210737664 |
---|---|
author | Höpfner, Friederike Paisdzior, Sarah Reininghaus, Nanina Sohail, Iqra Scheerer, Patrick Annibale, Paolo Biebermann, Heike Kühnen, Peter |
author_facet | Höpfner, Friederike Paisdzior, Sarah Reininghaus, Nanina Sohail, Iqra Scheerer, Patrick Annibale, Paolo Biebermann, Heike Kühnen, Peter |
author_sort | Höpfner, Friederike |
collection | PubMed |
description | The melanocortin-4 receptor (MC4R) is critical for central satiety regulation, therefore presenting a potent target for pharmacological obesity treatment. Melanocortin-4 receptor mutations prevalently cause monogenetic obesity. A possibility of overcoming stop mutations is aminoglycoside-mediated translational readthrough. Promising results were achieved in COS-7 cells, but data for human cell systems are still missing, so uncertainty surrounds this potential treatment. In transfected HEK-293 cells, we tested whether translational readthrough by aminoglycoside Geneticin combined with high-affinity ligand setmelanotide, which is effective in proopiomelanocortin or leptin receptor deficiency patients, is a treatment option for affected patients. Five MC4R nonsense mutants (W16X, Y35X_D37V, E61X, W258X, Q307X) were investigated. Confocal microscopy and cell surface expression assays revealed the importance of the mutations’ position within the MC4R. N-terminal mutants were marginally expressed independent of Geneticin treatment, whereas mutants with nonsense mutations in transmembrane helix 6 or helix 8 showed wild-type-like expression. For functional analysis, G(s) and G(q/11) signaling were measured. N-terminal mutants (W16X, Y35X_D37V) showed no cAMP formation after challenge with alpha-MSH or setmelanotide, irrespective of Geneticin treatment. Similarly, G(s) activation was almost impossible in W258X and Q307X with wild-type-like cell surface expression. Results for G(q/11) signaling were comparable. Based on our data, this approach improbably represents a therapeutic option. |
format | Online Article Text |
id | pubmed-9697516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96975162022-11-26 Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside Höpfner, Friederike Paisdzior, Sarah Reininghaus, Nanina Sohail, Iqra Scheerer, Patrick Annibale, Paolo Biebermann, Heike Kühnen, Peter Life (Basel) Article The melanocortin-4 receptor (MC4R) is critical for central satiety regulation, therefore presenting a potent target for pharmacological obesity treatment. Melanocortin-4 receptor mutations prevalently cause monogenetic obesity. A possibility of overcoming stop mutations is aminoglycoside-mediated translational readthrough. Promising results were achieved in COS-7 cells, but data for human cell systems are still missing, so uncertainty surrounds this potential treatment. In transfected HEK-293 cells, we tested whether translational readthrough by aminoglycoside Geneticin combined with high-affinity ligand setmelanotide, which is effective in proopiomelanocortin or leptin receptor deficiency patients, is a treatment option for affected patients. Five MC4R nonsense mutants (W16X, Y35X_D37V, E61X, W258X, Q307X) were investigated. Confocal microscopy and cell surface expression assays revealed the importance of the mutations’ position within the MC4R. N-terminal mutants were marginally expressed independent of Geneticin treatment, whereas mutants with nonsense mutations in transmembrane helix 6 or helix 8 showed wild-type-like expression. For functional analysis, G(s) and G(q/11) signaling were measured. N-terminal mutants (W16X, Y35X_D37V) showed no cAMP formation after challenge with alpha-MSH or setmelanotide, irrespective of Geneticin treatment. Similarly, G(s) activation was almost impossible in W258X and Q307X with wild-type-like cell surface expression. Results for G(q/11) signaling were comparable. Based on our data, this approach improbably represents a therapeutic option. MDPI 2022-11-05 /pmc/articles/PMC9697516/ /pubmed/36362948 http://dx.doi.org/10.3390/life12111793 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Höpfner, Friederike Paisdzior, Sarah Reininghaus, Nanina Sohail, Iqra Scheerer, Patrick Annibale, Paolo Biebermann, Heike Kühnen, Peter Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside |
title | Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside |
title_full | Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside |
title_fullStr | Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside |
title_full_unstemmed | Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside |
title_short | Evaluation of Pharmacological Rescue of Melanocortin-4 Receptor Nonsense Mutations by Aminoglycoside |
title_sort | evaluation of pharmacological rescue of melanocortin-4 receptor nonsense mutations by aminoglycoside |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697516/ https://www.ncbi.nlm.nih.gov/pubmed/36362948 http://dx.doi.org/10.3390/life12111793 |
work_keys_str_mv | AT hopfnerfriederike evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside AT paisdziorsarah evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside AT reininghausnanina evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside AT sohailiqra evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside AT scheererpatrick evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside AT annibalepaolo evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside AT biebermannheike evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside AT kuhnenpeter evaluationofpharmacologicalrescueofmelanocortin4receptornonsensemutationsbyaminoglycoside |